Artivion | CRY - Selling And Administration Expenses


Artivion reported $55.75M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 84.55M 6.21M Mar/2026
Baxter International USD 728M 33M Mar/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Boston Scientific USD 1.78B 53M Mar/2026
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 178.24M 21.79M Mar/2026
J&J USD 6.03B 719M Mar/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
ResMed USD 279.8M 1.4M Mar/2026
Stryker USD 2.15B 17M Mar/2026
Surmodics USD 11.4M 3.18M Jun/2025
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
Terumo JPY 114.81B 9.55B Mar/2026
Trinity Biotech USD 6.19M 2.18M Sep/2025